Potential Use of Riboflavin/UVA Cross-Linking in Bullous KeratopathyWollensak G.a · Aurich H.b · Wirbelauer C.b · Pham D.-T.b
aEye Laser Institute, Department of Ophthalmology, Martin Luther University, Halle, bDepartment of Ophthalmology, Vivantes-Klinikum Neukölln, Berlin, Germany Ophthalmic Res 2009;41:114–117 (DOI:10.1159/000187630)
Background: Collagen cross-linking of the cornea has been shown by us to have an antiedematous effect in the cornea. The aim of the present study was to examine if this effect can be used for the treatment of bullous keratopathy. Methods: This clinical interventional case series included 3 patients (3 eyes) with bullous keratopathy due to pseudophakia, corneal transplant rejection, and Fuchs’ endothelial dystrophy. After dehydration for 1 day using 40% glucose, the central 8 mm of the cornea were abraded and cross-linked with the photosensitizer riboflavin and UVA (370 nm, 3 mW/cm2) for 30 min. Optical coherence tomography pachymetry measurements of the central cornea were performed at various time intervals. Results: Corneal thickness was reduced by 90.33 ± 17.04 μm on average 3 days after cross-linking and by 93.67 ± 14.22 μm after 8 months. The bullous changes of the epithelium were markedly improved, resulting in loss of pain and discomfort. Visual acuity was significantly improved in the case without prior stromal scarring. Conclusions: Cross-linking might become another useful tool in the treatment of bullous keratopathy. It is primarily suited for patients with pain symptoms, restricted visual prognosis or to extend the time interval for an upcoming corneal transplantation.
|Direct payment||This item at the regular price: USD 33.00|
|Payment from account||With a Karger Pay-per-View account (down payment USD 150)
you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00